Table 3.
PISQ-IR 1 mean scores of our sample and from the literature[23]
| Mean scores ± SD of women with FGM/C | Mean scores ± SD of women without FGM/C | ||||
|---|---|---|---|---|---|
| All (n = 124) | I (n = 9) | II (n = 41) | III (n = 74) | With PFD2 | |
| PISQ-IR1 | |||||
| SA-AO1 | 3.3 ± 1.1 (n = 85) | 3.2 ± 0.9 (n = 8) | 3.5 ± 0.9 (n = 27) | 3.3 ± 1.2 (n = 50) | 3.4 ± 0.8 |
| SA-PR1 | 3.4 ± 0.6 (n = 84) | 3.8 ± 0.3 (n = 8) | 3.4 ± 0.7 (n = 27) | 3.4 ± 0.7 (n = 49) | 3.2 ± 0.7 |
| SA-CS1 | 4.5 ± 0.8 (n = 84) | 4.8 ± 0.4 (n = 8) | 4.5 ± 1.1 (n = 27) | 4.5 ± 0.7 (n = 49) | 4.4 ± 0.7 |
| SA-CI1 | 3.8 ± 0.5 (n = 82) | 3.9 ± 0.2 (n = 8) | 3.7 ± 0.6 (n = 26) | 3.8 ± 0.5 (n = 48) | 3.0 ± 0.9 |
| SA-D1 | 2.9 ± 1.0 (n = 83) | 2.8 ± 1.2 (n = 8) | 3.0 ± 1.0 (n = 26) | 2.9 ± 1.0 (n = 49) | 3.0 ± 0.9 |
| SA-GQ1 | 3.9 ± 1.1 (n = 80) | 3.5 ± 1.3 (n = 8) | 3.7 ± 1.2 (n = 26) | 4.1 ± 1.0 (n = 46) | 3.0 ± 1.1 |
| NSA-CS1 | 1.5 ± 0.7 (n = 37) | 1.0 ± 0.0 (n = 1) | 1.4 ± 0.5 (n = 13) | 1.5 ± 0.8 (n = 23) | 2.8 ± 1.0 |
| NSA-PR1 | 2.6 ± 0.8 (n = 35) | 2.5 ± 0.0 (n = 1) | 2.6 ± 1.0 (n = 11) | 2.6 ± 0.8 (n = 23) | 2.2 ± 1.0 |
| NSA-CI1 | 1.2 ± 0.6 (n = 36) | 1.0 ± 0.0 (n = 1) | 1.1 ± 0.3 (n = 13) | 1.3 ± 0.7 (n = 22) | 2.1 ± 0.1 |
| NSA-GQ1 | 2.3 ± 1.2 (n = 37) | 1.5 ± 0.0 (n = 1) | 2.0 ± 1.2 (n = 13) | 2.6 ± 1.2 (n = 23) | 2.9 ± 1.2 |
1Pelvic organ prolapse Incontinence Sexual Questionnaire—IUGA Revised (PISQ-IR) for Sexually Active (SA) and Non-Sexually Active (NSA), Arousal and Orgasm (AO), Partner-Related impact on activity/inactivity (PR), Condition-Specific impact on activity/inactivity (CS), Condition-specific Impact on quality (CI), Desire (D), and Global Quality (GQ)
2Pelvic floor dysfunction (urinary incontinence and/or pelvic organ prolapse and/or fecal incontinence)